Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 421

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial

Xu, Bo, Tu, Shengxian, Song, Lei, Jin, Zening, Yu, Bo, Fu, Guosheng, Zhou, Yujie, Wang, Jian’an, Chen, Yundai, Pu, Jun, Chen, Lianglong, Qu, Xinkai, Yang, Junqing, Liu, Xuebo, Guo, Lijun, Shen, Chengxing, Zhang, Yaojun, Zhang, Qi, Pan, Hongwei, Fu, Xiaogang, Liu, Jian, Zhao, Yanyan, Escaned, Javier, Wang, Yang, Fearon, William F, Dou, Kefei, Kirtane, Ajay J, Wu, Yongjian, Serruys, Patrick W, Yang, Weixian, Wijns, William, Guan, Changdong, Leon, Martin B, Qiao, Shubin, Stone, Gregg W·2021·The Lancet

Abstract

BACKGROUND Compared with visual angiographic assessment, pressure wire-based physiological measurement more accurately identifies flow-limiting lesions in patients with coronary artery disease. Nonetheless, angiography remains the most widely used method to guide percutaneous coronary intervention (PCI). In FAVOR III China, we aimed to establish whether clinical outcomes might be improved by lesion selection for PCI using the quantitative flow ratio (QFR), a novel angiography-based approach to estimate the fractional flow reserve. METHODS FAVOR III China is a multicentre, blinded, randomised, sham-controlled trial done at 26 hospitals in China. Patients aged 18 years or older, with stable or unstable angina pectoris or patients who had a myocardial infarction at least 72 h before screening, who had at least one lesion with a diameter stenosis of 50-90% in a coronary artery with a reference vessel of at least 2·5 mm diameter by visual assessment were eligible. Patients were randomly assigned to a QFR-guided strategy (PCI performed only if QFR ≤0·80) or an angiography-guided strategy (PCI based on standard visual angiographic assessment). Participants and clinical assessors were masked to treatment allocation. The primary endpoint was the 1-year rate of major adverse cardiac events, a composite of death from any cause, myocardial infarction, or ischaemia-driven revascularisation. The primary analysis was done in the intention-to-treat population. The trial was registered with ClinicalTrials.gov (NCT03656848). FINDINGS Between Dec 25, 2018, and Jan 19, 2020, 3847 patients were enrolled. After exclusion of 22 patients who elected not to undergo PCI or who were withdrawn by their physicians, 3825 participants were included in the intention-to-treat population (1913 in the QFR-guided group and 1912 in the angiography-guided group). The mean age was 62·7 years (SD 10·1), 2699 (70·6%) were men and 1126 (29·4%) were women, 1295 (33·9%) had diabetes, and 2428 (63·5%) presented with an acute coronary syndrome. The 1-year primary endpoint occurred in 110 (Kaplan-Meier estimated rate 5·8%) participants in the QFR-guided group and in 167 (8·8%) participants in the angiography-guided group (difference, -3·0% [95% CI -4·7 to -1·4]; hazard ratio 0·65 [95% CI 0·51 to 0·83]; p=0·0004), driven by fewer myocardial infarctions and ischaemia-driven revascularisations in the QFR-guided group than in the angiography-guided group. INTERPRETATION In FAVOR III China, among patients undergoing PCI, a QFR-guided strategy of lesion selection improved 1-year clinical outcomes compared with standard angiography guidance. FUNDING Beijing Municipal Science and Technology Commission, Chinese Academy of Medical Sciences, and the National Clinical Research Centre for Cardiovascular Diseases, Fuwai Hospital.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02248-0

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 421

Metadata

Authors
Xu, B., Tu, S., Song, L., Jin, Z., Yu, B., Fu, G., Zhou, Y., Wang, J., Chen, Y., Pu, J., Chen, L., Qu, X., Yang, J., Liu, X., Guo, L., Shen, C., Zhang, Y., Zhang, Q., Pan, H., Fu, X., Liu, J., Zhao, Y., Escaned, J., Wang, Y., Fearon, W. F., Dou, K., Kirtane, A. J., Wu, Y., Serruys, P. W., Yang, W., Wijns, W., Guan, C., Leon, M. B., Qiao, S., & Stone, G. W.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-12
Volume
398
Issue
10317
Pages
2149-2159
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3209670581
Cited by
421
References
18
FWCI
52.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02248-0
The paper
Xu, B., Tu, S., Song, L., Jin, Z., Yu, B., Fu, G., Zhou, Y., Wang, J., Chen, Y., Pu, J., Chen, L., Qu, X., Yang, J., Liu, X., Guo, L., Shen, C., Zhang, Y., Zhang, Q., Pan, H., . . . Stone, G. W. (2021). Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)02248-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.